Drugs Made In America Acquisition
DMAA | NASDAQ
$10.90
$0.00 (0.00%)
At close: Nov 16, 2026, 4:00 PM ET
$10.89
-$0.01 (-0.09%)
After-hours:
Nov 16, 2026, 4:37 PM ET
+0.00%
(1D)No price chart data available for 1D timeframe.
Rating
11.2
+1.4 ptsFundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #1256/1269 (Top 99%)
Key Statistics
Market Data
Market Cap $264.62M
1D Range
10.89 10.93
52W Range
10.32 10.93
Valuation (TTM)
PE 54.50
PB 1.92
EV/EBITDA -100.84
Valuation (NTM)
Forward PE N/A
Forward PEG -0.56
Price Target $0.00
Cash Flow
FCF Yield -0.1%
SBC Adj. FCF Yield -0.1%
SBC Impact N/A
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y N/A |
N/A
FCF 3Y | 5Y N/A |
N/A
Returns
ROA 4.2%
ROE 2.9%
ROIC -1.8%
Financial Health
Net Debt
$929.72K
Current Ratio 0.02
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or oth...
Sector Financial Services
Industry Shell Companies
Employees 2
IPO Date Jan 27, 2025
Website dmaacorp.com
Fiscal Year January - December
Latest News
No news articles available yet.
Add to Watchlist
Select watchlists to add or remove DMAA